CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.42, no.1, pp.40-47, 2018 (SCI-Expanded)
Background: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression.